| 1 |
35088582 | Genetic Aberrations and Interaction of NEK2 and TP53 Accelerate Aggressiveness of Multiple Myeloma. | 2022 Mar |
2 |
| 2 |
34025442 | Proteasome Inhibition Suppresses KIT-Independent Gastrointestinal Stromal Tumors Via Targeting Hippo/YAP/Cyclin D1 Signaling. | 2021 |
1 |
| 3 |
34589431 | Four and a Half LIM Domains Protein 2 Mediates Bortezomib-Induced Osteogenic Differentiation of Mesenchymal Stem Cells in Multiple Myeloma Through p53 Signaling and β-Catenin Nuclear Enrichment. | 2021 |
2 |
| 4 |
34608124 | Severe cellular stress activates apoptosis independently of p53 in osteosarcoma. | 2021 Oct 4 |
2 |
| 5 |
35071005 | Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments. | 2021 |
1 |
| 6 |
32123008 | NRF3-POMP-20S Proteasome Assembly Axis Promotes Cancer Development via Ubiquitin-Independent Proteolysis of p53 and Retinoblastoma Protein. | 2020 Apr 28 |
2 |
| 7 |
32235770 | Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors. | 2020 Mar 22 |
1 |
| 8 |
32446382 | Kuanoniamine C stimulates bortezomib-induced cell death via suppression of glucose-regulated protein 78 in osteosarcoma. | 2020 Jun 18 |
1 |
| 9 |
32798402 | [Clinical Efficacy and Prognosis of Double-Hit Multiple Myeloma Patients with Deletion P53 Treated with Regimen Based on Bortezomib]. | 2020 Aug |
2 |
| 10 |
33163985 | Synthetic Lethal Drug Combinations Targeting Proteasome and Histone Deacetylase Inhibitors in TP53-Mutated Cancers. | 2020 |
1 |
| 11 |
30365089 | Mechanisms underlying the increased chemosensitivity of bortezomib-resistant multiple myeloma by silencing nuclear transcription factor Snail1. | 2019 Jan |
2 |
| 12 |
30554133 | In HPV-Positive HNSCC Cells, Functional Restoration of the p53/p21 Pathway by Proteasome Inhibitor Bortezomib Does Not Affect Radio- or Chemosensitivity. | 2019 Mar |
2 |
| 13 |
30936194 | Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers. | 2019 Apr |
1 |
| 14 |
31482012 | Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress. | 2019 |
3 |
| 15 |
29269566 | Bortezomib sensitizes thyroid cancer to BRAF inhibitor in vitro and in vivo. | 2018 Jan |
1 |
| 16 |
29569972 | Expression of TRIM28 correlates with proliferation and Bortezomib-induced apoptosis in B-cell non-Hodgkin lymphoma. | 2018 Nov |
1 |
| 17 |
30214587 | Sequential treatment with celecoxib and bortezomib enhances the ER stress-mediated autophagy-associated cell death of colon cancer cells. | 2018 Oct |
2 |
| 18 |
27903750 | Nuclear Export of Ubiquitinated Proteins Determines the Sensitivity of Colorectal Cancer to Proteasome Inhibitor. | 2017 Apr |
4 |
| 19 |
28679691 | Metastatic triple-negative breast cancer patient with TP53 tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events. | 2017 Jul |
2 |
| 20 |
28710427 | The essential role of TAp73 in bortezomib-induced apoptosis in p53-deficient colorectal cancer cells. | 2017 Jul 14 |
4 |
| 21 |
28798402 | Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis. | 2017 Aug 11 |
3 |
| 22 |
27123085 | Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3. | 2016 May |
1 |
| 23 |
27626308 | The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma. | 2016 Oct 25 |
2 |
| 24 |
27822577 | Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment. | 2016 Dec 20 |
7 |
| 25 |
25530422 | The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer. | 2015 Aug 1 |
2 |
| 26 |
26354682 | Hypoxia Promotes Synergy between Mitomycin C and Bortezomib through a Coordinated Process of Bcl-xL Phosphorylation and Mitochondrial Translocation of p53. | 2015 Dec |
1 |
| 27 |
26378933 | Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma. | 2015 |
1 |
| 28 |
26544558 | Synergistic Effect and Molecular Mechanism of Homoharringtonine and Bortezomib on SKM-1 Cell Apoptosis. | 2015 |
1 |
| 29 |
24125776 | The use of hollow mesoporous silica nanospheres to encapsulate bortezomib and improve efficacy for non-small cell lung cancer therapy. | 2014 Jan |
2 |
| 30 |
24380881 | HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib. | 2014 Apr |
2 |
| 31 |
24485799 | Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. | 2014 Apr |
2 |
| 32 |
24632713 | Targeting MUC1-C is synergistic with bortezomib in downregulating TIGAR and inducing ROS-mediated myeloma cell death. | 2014 May 8 |
1 |
| 33 |
23064281 | Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines. | 2013 Jan |
1 |
| 34 |
23357978 | Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB. | 2013 Mar 15 |
1 |
| 35 |
23421999 | Liberation of functional p53 by proteasome inhibition in human papilloma virus-positive head and neck squamous cell carcinoma cells promotes apoptosis and cell cycle arrest. | 2013 Mar 15 |
3 |
| 36 |
23635777 | Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma. | 2013 Jun |
2 |
| 37 |
22324515 | Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells. | 2012 Jun |
1 |
| 38 |
22559167 | Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model. | 2012 May 4 |
1 |
| 39 |
22964432 | Roles of estrogen receptor and p21(Waf1) in bortezomib-induced growth inhibition in human breast cancer cells. | 2012 Nov |
2 |
| 40 |
23226303 | Bortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young mice. | 2012 |
1 |
| 41 |
21139584 | Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma. | 2011 Jan 4 |
1 |
| 42 |
21224072 | Proteasome inhibitors induce p53-independent apoptosis in human cancer cells. | 2011 Jan |
2 |
| 43 |
21273177 | Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trial. | 2011 Jan |
2 |
| 44 |
21297663 | Myc overexpression brings out unexpected antiapoptotic effects of miR-34a. | 2011 Jun 2 |
1 |
| 45 |
21454483 | Inhibition of p53 DNA binding function by the MDM2 protein acidic domain. | 2011 May 6 |
1 |
| 46 |
21459798 | Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway. | 2011 May 15 |
2 |
| 47 |
21532991 | p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. | 2011 Apr 21 |
1 |
| 48 |
19608275 | Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. | 2010 Jan |
1 |
| 49 |
20006625 | Bortezomib suppresses focal adhesion kinase expression via interrupting nuclear factor-kappa B. | 2010 Jan 30 |
1 |
| 50 |
20096120 | Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. | 2010 Jan 22 |
6 |